The USFDA classified the GMP inspection of Dr. Reddy’s Laboratories Limited’s formulations manufacturing facility FTO-3 in Bachupally, Hyderabad, as ‘Voluntary Action Indicated (VAI)’ and officially closed it under 21 CFR 20.64(d)(3).
RDY · Dr Reddys Laboratories Ltd
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 59%
- Last earnings
- Oct 23, 2026
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Dr. Reddy’s Laboratories Limited said management will hold in-person group meetings with institutional investors in Mumbai on 16.11.2026 and London on 17.11.2026 – 18.11.2026.
Dr. Reddy’s Laboratories Ltd. said Brazil’s National Health Surveillance Agency (ANVISA) granted marketing authorization for generic semaglutide injection for adults with insufficiently controlled type 2 diabetes mellitus. The company plans to launch the once-weekly treatment in Brazil with Aché.
Dr. Reddy’s Laboratories Limited allotted 5,91,270 fully paid equity shares of Re.1/- each on November 4, 2026 to eligible employees exercising options under Dr. Reddy’s Employees ADR Stock Options Scheme, 2007.
Dr. Reddy’s Laboratories Limited furnished the earnings call transcript for the quarter and half year ended September 30, 2026, following the October 23, 2026 call.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RDY
this stock
Dr Reddys Laboratories Ltd
|
$12.41B | +6.1% | — | — | 3.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$69.55B | +39.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$50.29B | +4.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.77B | +25.7% | +4.3% | 89.2 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 106
The USFDA classified the GMP inspection of Dr. Reddy’s Laboratories Limited’s formulations manufacturing facility FTO-3 in Bachupally, Hyderabad, as ‘Voluntary Action Indicated (VAI)’ and officially closed it under 21 CFR 20.64(d)(3).
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RDY | +1.0% | +12.7% | +14.3% | +5.1% | +6.1% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +9.6% | +22.0% | +23.5% | +13.8% | +4.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.